Table 2 Median and interquartile range (Q1–Q3) of different parameters at different follow-up time in mCNV patients.

From: Retinal vascular changes and aqueous humor cytokines changes after aflibercept intravitreal injection in treatment-naïve myopic choroidal neovascularization

 

T0

T1

T2

p-value a

BCVA (logMAR)

0.6 (0.5–0.8)

0.3 (0.3–0.4)*

0.3 (0.3–0.4)

< 0.001

FA Leakage

2 (2–2)

—

0 (0–0.3)

0.003 b

FA area (mm2)

0.8 (0.5–3)

—

0.5 (0.3–1.5)

0.005 b

OCTA Selected Area (mm2)

0.9 (0.5–2.9)

0.6 (0.3–2)*

0.5 (0.2–1.5)

0.005

OCTA Flow Area (mm2)

0.5 (0.3–1.5)

0.3 (0.2–0.9)*

0.3 (0.1–0.6)

0.013

CRT (µm)

387.5 (331.0–435.8)

285.0 (257.5–333.5)*

267.0 (255.3–314.5)

< 0.001

ELM visualization

0 (0–0)

2 (1.7–2)*

2 (1.8–2)

< 0.001

PlGF (pg/ml)

1.8 (1.5–2.9)

1.4 (1.1–1.9)*

—

0.019 b

VEGF (pg/ml)

3.4 (2–5.6)

0.5 (0.1–0.9)*

—

0.008 b

  1. BCVA, best corrected visual acuity; FA, fluorescein angiography; OCTA, optical coherence tomography angiography; CRT, central retinal thickness; ELM, external limiting membrane; PlGF, placental growth factor; VEGF, vascular endothelial growth factor.
  2. aFriedman test; bWilcoxon U test.
  3. *p < 0.05 post hoc analysis respect to previous follow-up control.
Back to article page